Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Łukasz Galus
Observed names:
Galus, Łukasz,
L. Galus,
Lukasz Galus,
Ł. Galus
Institution:
Greater Poland Cancer Center
Observed institutions:
Poznan University of Medical Sciences,
Heliodor Swiecicki Clinical Hospital,
Greater Poland Cancer Center
ORCID:
0000-0002-9515-1834
Observed ORCID:
0000-0002-9515-1834
OpenAlex ID:
A5050927742
Vitamin D supplementation increases objective response rate and prolongs progression‐free time in patients with advanced melanoma undergoing anti–PD‐1 therapy
2023
·
Łukasz Galus
, Michał Michalak
, et al.
·
Cancer
·
57
PDF
A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
2022
·
Bernadeta Pietrzak
, Katarzyna Tomela
, et al.
·
Cancers
·
36
PDF
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
2018
·
Izabela Łasińska
, Tomasz Kolenda
, et al.
·
Anti-Cancer Agents in Medicinal Chemistry
·
32
Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
2024
·
Natalia Szóstak
, Luiza Handschuh
, et al.
·
Cancer Immunology Research
·
26
PDF
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
2023
·
Katarzyna Tomela
, Bernadeta Pietrzak
, et al.
·
Cells
·
24
PDF
The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression
2021
·
Joanna Patrycja Wróblewska
, Michał Stefan Lach
, et al.
·
Cancers
·
24
PDF
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma
2020
·
Bożena Cybulska-Stopa
, Paweł Rogala
, et al.
·
Melanoma Research
·
24
MiRNAs from serum-derived extracellular vesicles as biomarkers for uveal melanoma progression
2022
·
Joanna Patrycja Wróblewska
, Michał Stefan Lach
, et al.
·
Frontiers in Cell and Developmental Biology
·
22
Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
2019
·
Tomasz Kolenda
, Piotr Rutkowski
, et al.
·
Oncotarget
·
21
PDF
Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
2018
·
Eliza Kwiatkowska-Borowczyk
, Patrycja Czerwińska
, et al.
·
OncoImmunology
·
20
PDF
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
2023
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Melanoma Research
·
17
Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence
2020
·
Bożena Cybulska-Stopa
, Paweł Rogala
, et al.
·
Advances in Medical Sciences
·
17
First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland
2020
·
Bożena Cybulska-Stopa
, Renata Pacholczak-Madej
, et al.
·
Immunotherapy
·
16
Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
2020
·
Patrycja Czerwinska
, Marcin Rucinski
, et al.
·
OncoImmunology
·
15
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
2023
·
Joanna Placzke
, Magdalena Rosińska
, et al.
·
Cancers
·
14
PDF
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors
2018
·
Paweł Teterycz
, Paulina Jagodzińska-Mucha
, et al.
·
Melanoma Research
·
13
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Cancers
·
10
PDF
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Journal of Clinical Medicine
·
10
PDF
Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
2021
·
Anna Przybyla
, Alexander A. Lehmann
, et al.
·
Cancers
·
10
PDF
Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients
2023
·
Paula Kamińska
, Karolina Buszka
, et al.
·
Cells
·
8
PDF
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
2023
·
Karolina Piejko
, Bożena Cybulska-Stopa
, et al.
·
Targeted Oncology
·
8
PDF
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
2021
·
Bożena Cybulska-Stopa
, Marcin Ziętek
, et al.
·
Journal of Dermatological Treatment
·
8
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
2020
·
Bożena Cybulska-Stopa
, Marcin Ziętek
, et al.
·
Melanoma Research
·
8
Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy
2025
·
Natalia Szóstak
, Michał Budnik
, et al.
·
Cancer Immunology Immunotherapy
·
7
Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.
2021
·
Bozena Cybulska-Stopa
, Marcin Zietek
, et al.
·
Journal of Clinical Oncology
·
5
Show more works
View as search
Works count:
86
Citation count:
485
H-index:
14
I10-index:
19
Year
Topic
Type
